Skip to main content
SpringerLink
Log in

Update on the Current Status and Indications for Transcatheter Edge-to-Edge Mitral Valve Repair

  • Valvular Heart Disease (TL Kiefer, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review the current status and indications of transcatheter edge-to-edge mitral valve repair.

Recent Findings

Mitral regurgitation remains a common valvular disease and can be classified as degenerative (primary) or functional (secondary). Randomized controlled trials have shown that transcatheter edge-to-edge mitral valve repair with MitraClip is successful, safe, and effective in reducing mitral regurgitation. The US Food and Drug Administration approved MitraClip in 2013 for treatment of patients with primary mitral regurgitation at prohibitive surgical risk and in 2019 for secondary mitral regurgitation. Several MitraClip generations exist (NT/R, XT/R, NTW, and XTW) with unique features and considerations. Additional edge-to-edge repair, non-edge-to-edge repair, and transcatheter valve replacement systems are under investigation as stand-alone or adjunctive therapy for patients with mitral regurgitation.

Summary

Mitral regurgitation remains a significant health burden and many patients are not suitable for surgical repair or replacement. Transcatheter mitral valve therapies can be considered in selected patients and are safe and effective. More research is needed to understand how to best select devices and patients and optimize outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373:1382–94.

    Article  Google Scholar 

  2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.

    Article  Google Scholar 

  3. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease--current management and future challenges. Lancet. 2016;387:1324–34.

    Article  Google Scholar 

  4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force On Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.

    Article  Google Scholar 

  5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014;148:e1–e132.

    Article  Google Scholar 

  6. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358–65.

    Article  Google Scholar 

  7. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.

    Article  CAS  Google Scholar 

  8. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–54.

    Article  Google Scholar 

  9. Saibal Kar DL, Smalling R, Whisenant B, Rammohan C, Fail P, Rinaldi M, et al. The EVEREST II realism continued access study: effectiveness of transcatheter reduction of significant mitral regurgitation in surgical candidates. J Am Coll Cardiol. 2013;61(Supplement):E1959.

    Google Scholar 

  10. Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64:172–81.

    Article  Google Scholar 

  11. Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012;59:130–9.

    Article  Google Scholar 

  12. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.

    Article  Google Scholar 

  13. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297–306.

    Article  Google Scholar 

  14. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. J Am Coll Cardiol Img. 2019;12:353–62.

    Article  Google Scholar 

  15. Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR Jr, Stebbins A, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70:2315–27.

    Article  Google Scholar 

  16. • Chhatriwalla AK, Vemulapalli S, Szerlip M, et al. Operator experience and outcomes of transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2019;74:2955–65 This study highlighted the importance of operator experience in achieving better outcomes with the MitraClip device.

    Article  Google Scholar 

  17. • Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT registry. JACC Cardiovasc Interv. 2019;12:1342–52 This study highlighted the importance of institutional experience in achieving better outcomes with the MitraClip device.

    Article  Google Scholar 

  18. •• Raghunathan D, Garcia-Sayan E, Schechter M, Napierkowski S, Dhoble A, Smalling R. First-in-human report of mitraclip g4 implantation for torrential tricuspid regurgitation and severe secondary mitral regurgitation. JACC Cardiovasc Interv. 2020;13:1599–602 This is the first-in-human report of using the MitraClip G4 and highlighted its new features.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Structural Heart Disease, Division of Cardiology, Henry Ford Health System, Detroit, MI, USA

    Mohammed Qintar

  2. Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City, 4401 Wornall Road, Kansas City, MO, 64111, USA

    Mohammed Qintar & Adnan K. Chhatriwalla

Authors
  1. Mohammed Qintar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adnan K. Chhatriwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed Qintar.

Ethics declarations

Conflict of Interest

Adnan K. Chhatriwalla reports being on the speakers’ bureau for Edwards Lifesciences, Medtronic Inc., and Abbott Vascular; being a proctor for Edwards Lifesciences and Medtronic, Inc.; receiving research support from Boston Scientific; and consulting support from Boston Scientific and Silk Road Medical.

Mohammed Qintar has no relevant relationships to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Valvular Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qintar, M., Chhatriwalla, A.K. Update on the Current Status and Indications for Transcatheter Edge-to-Edge Mitral Valve Repair. Curr Cardiol Rep 22, 135 (2020). https://doi.org/10.1007/s11886-020-01391-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-020-01391-1

Keywords

Search

Navigation